Print

Data From Merck & Co., Inc. (MRK)’s Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for Study of Liver Diseases Annual Meeting  
10/1/2013 9:57:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the company’s investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013. \

Help employers find you! Check out all the jobs and post your resume.

//-->